Energy, Republic of Korea

Ensol Biosciences is a South Korean biotechnology company specializing in the discovery and development of peptide-based therapeutics using its proprietary bio-big data platform. The company's core technology, KISDD and ETONS, enables the identification of candidate substances that regulate disease-specific protein-protein interactions. Its lead program, Brp-004 (Peniel 2000), is a first-in-class peptide drug for degenerative disc disease that has been out-licensed to Yuhan Corporation and subsequently to Spine BioPharma for global development. Ensol Biosciences is also advancing a diverse pipeline targeting osteoarthritis, Alzheimer's disease, and various oncology indications, positioning itself as a leader in computer-aided drug design within the Korean biotech ecosystem.